Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Pituitary adenomas (PAs) are neoplasms derived from the endocrine cells of the anterior
pituitary gland. Most frequently, they are benign tumors, but may sometimes display an …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

In the 2022 fifth edition of the WHO Classification of Endocrine Tumours and of Central
Nervous System Tumours, pituitary adenomas are reclassified as neuroendocrine tumours …

The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …

Objective A somatic mutational hotspot in the SF3B1 gene was reported in lactotroph
tumours. The aim of our study was to examine the prevalence of driver SF3B1 variants in a …

Cushing disease caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary
corticotroph adenoma leads to hypercortisolaemia with high mortality due to metabolic …

Pituitary tumors are rare neoplasms, with a heterogeneous biological and clinical behavior,
due to their clinical course, local invasive growth, resistance to conventional therapies and …

Acromegaly is a rare disease with prevalence of approximately 60 cases per million, slight
female predominance and peak onset in adults in the fourth decade. Clinical diagnosis is …

Radiotherapy, conventional or radiosurgery, has been used to control prolactin secretion
and tumour growth in prolactinomas both as part of multimodal therapy or rarely as primary …